Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series.
- DOI
- 10.1016/j.braindev.2026.104598
- Published
- 2026 Sep 21
- Container
- Brain & development
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.braindev.2026.104598,
title = {Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series.},
author = {Garcia RV and Del Rocio Quiroz Saavedra A and Buompadre MC and Ramos MP and Monti ML and Tenembaum SN and Savransky AG},
year = {2026},
journal = {Brain \& development},
doi = {10.1016/j.braindev.2026.104598},
url = {https://doi.org/10.1016/j.braindev.2026.104598}
}RIS
TY - JOUR TI - Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series. AU - Garcia RV AU - Del Rocio Quiroz Saavedra A AU - Buompadre MC AU - Ramos MP AU - Monti ML AU - Tenembaum SN AU - Savransky AG PY - 2026 JO - Brain & development DO - 10.1016/j.braindev.2026.104598 UR - https://doi.org/10.1016/j.braindev.2026.104598 ER -
APA
RV, G., A, D. R. Q. S., MC, B., MP, R., ML, M., SN, T., & AG, S. (2026). Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series.. Brain & development. https://doi.org/10.1016/j.braindev.2026.104598
Source records
- pubmed · retrieved 2026-09-25T20:14:56.974Z